Prognostic value of procalcitonin in community-acquired pneumonia

European Respiratory Journal

Volumn 37, Issue 2, 2011, Pages 384-392

  Schuetz, P ^a   Suter Widmer, I ^b   Chaudri, A ^b   Christ Crain, M ^b   Zimmerli, W ^c   Mueller, B ^a,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d Kantonsspital Aarau ^*  (Switzerland)

Author keywords

CURB65; Mortality; Pneumonia; Pneumonia severity index; Procalcitonin

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN; UREA;

ADULT; AGED; ARTICLE; BREATHING RATE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CALCITONIN; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; CONFUSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROGNOSIS; PROTEIN PRECURSORS; RESPIRATION; ROC CURVE; SEVERITY OF ILLNESS INDEX; UREA;

EID: 79953659971     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00035610     Document Type: Article

References (26)

1. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754. (Pubitemid 32578779)
2. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-1180. (Pubitemid 41829947)
3. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl J Med 1997; 336: 243-250. (Pubitemid 27044625)
4. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-382. (Pubitemid 36560938)
5. Schuetz P, Koller M, Christ-Crain M, et al. Predicting mortality with pneumonia severity scores: importance of model recalibration to local settings. Epidemiol Infect 2008; 136: 1628-1637.
6. Schuetz P, Christ-Crain M, Muller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections - hope for hype? Swiss Med Wkly 2009; 139: 318-326.
7. Jensen JU, Heslet L, Jensen TH, et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006; 34: 2596-2602. (Pubitemid 44413058)
8. Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006; 32: 469-472. (Pubitemid 43289660)
9. Haeuptle J, Zaborsky R, Fiumefreddo R, et al. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis 2009; 28: 55-60.
10. Muller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007; 7: 10.
11. Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008; 31: 349-355.
12. Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008; 52: 48-58.
13. Schuetz P, Christ-Crain M, Wolbers M, et al. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res 2007; 7: 102.
14. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl. 2, S27-S72. (Pubitemid 46290553)
15. Schuetz P, Albrich W, Christ-Crain M, et al. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010; 5: 575-587.
16. PencinaMJ, D'Agostino RB Sr,D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172.
17. Neill AM, Martin IR, Weir R, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51: 1010-1016. (Pubitemid 26360177)
18. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375: 463-474.
19. Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Int Med 2008; 168: 2000-2007.
20. Schuetz P, Christ-Crain M, Wolbers M, et al. Effect of procalcitonin-based guidelines compared to standard guidelines on antibiotic use in lower respiratory tract infections: the randomized-controlled multicenter ProHOSP trial. JAMA 2009; 302: 1059-1066.
21. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363: 600-607. (Pubitemid 38264177)
22. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 84-93. (Pubitemid 43955248)
23. Menendez R, Martinez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009; 64: 587-591.
24. Menendez R, Martinez R, Reyes S, et al. Stability in community-acquired pneumonia: one step forward with markers?Thorax 2009; 64: 987-992.
25. Masia M, Gutierrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005; 128: 2223-2229. (Pubitemid 41507563)
26. Muller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010; 138: 121-129.